drugset
drugset / Trial / NCT01084044

Effects of Ulinastatin on Coagulation in High Risk Patients Undergoing Off Pump Coronary Artery Bypass Graft Surgery

NCT01084044 ↗

Phase 4 Completed 80 enrolled Yonsei University
RandomizedParallel-groupDouble-blindTreatment

Summary

Ulinastatin reduce the amount of bleeding and fibrinolysis in high risk patients undergoing off-pump coronary bypass surgery (OPCAB).

Timeline

Start
2010-01
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulinastatin Protein / enzyme biologic 300000 iu —

Indications

coronary artery disorder